20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, pharmaceutical companies, and other stakeholders to easily integrate ICER-generated analyses and curated content into their formulary, benefit design, and pricing strategy.

At this week’s Annual Meeting of ISPOR, the Institute for Clinical and Economic Review (ICER) announced it will be developing two new tools to enhance the ability of payers, pharmaceutical companies, patient groups, and other stakeholders to quickly examine ICER’s entire body of work and generate actionable summaries, allowing them to more readily use this work in a variety of strategic decisions. 

The entirety of each individual ICER assessment will remain in the public domain and free for anyone to access through the ICER Evidence Reports. These new decision-support tools – the ICER Evidence Compendium and the ICER Interactive Modeler – will be subscription-based products intended to make the entire body of past and present ICER work easier to search, to analyze, and to apply to a wide variety of policy and decision-making platforms.

Read ICER announcement